GENE ONLINE|News &
Opinion
Blog

2023-06-16| R&D

Cholera-causing Bacteria Prey on Human Immune Cells by Forming Biofilms

by GeneOnline
Share To

A new study from the University of Basel, Switzerland, has shown that Vibrio cholerae, the bacteria responsible for cholera, forms a unique type of biofilm on immune cells. The findings published in Cell provide new understandings on the way bacteria employ biofilms.  

Related Article: Overcoming Immune Evasion in CAR-T Therapies with Groundbreaking New Discoveries  

New Discovery in Biofilms Survival Strategies 

The formation of biofilms has previously been recognized as a bacterial defense mechanism. Biofilms are clusters of bacteria that aggregate in a self-produced matrix. One of the major concerns with biofilms is that they may contain human infectious agents, like Vibrio cholerae. The biofilm can confer protection against hostile conditions and the immune system’s response. 

The researchers focused on exploring the interactions between Vibrio cholerae and immune cells and the function of biofilms in the interaction. They discovered that not only does biofilm formation in V. cholerae protect the bacteria, but it also acts aggressively towards immune cells. The team of researchers focused on biofilm formation on macrophages and found that the mechanisms utilized in the formation were different than those of other surfaces. They observed that the biofilms encased the immune cells, after which they went on to locally establish a high concentration of a toxin, hemolysin, that kills the cells.

Insights in Biofilms Enable More Effective Defense Against Pathogens

Understanding biofilms is important because they can be both helpful and detrimental to humans since they may contain both harmful and helpful bacteria. Although this aggressive attack was discovered in V. cholerae biofilms, further investigation into the formation of other pathogens’ biofilms is needed to explore if they also attack immune cells in the same way. It is imperative to gain insight into pathogens’ attack strategies to develop innovative approaches to fighting them.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
LATEST
Pfizer’s Q1 2024 Revenue Declines, Offset by Strong Performance of Non-COVID-19 Products
2024-05-03
Novo Nordisk Revises Outlook: Reports 24% Growth in Q1 2024 Sales, Reaching DKK 65.3 Billion
2024-05-03
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
EVENT
Scroll to Top